SC-37681
SC-37681 Uses, Dosage, Side Effects, Food Interaction and all others data.
SC-37681 is a prostaglandin E1 (PGE1) analog and antiprogestogen used for preoperative dilation of the cervix before surgical abortion. It is available as vaginal suppositories and also used in combination with the antiprogestin and mifepristone for termination of 1st- and 2nd-trimester pregnancy . It is not FDA-approved but available in Japan marketed as Preglandin.
SC-37681 softens and dilates of the cervix prior to transcervical intrauterine operative procedures. It is a prostaglandin E1 analog that potently stimulates uterine contractions and causes cervical ripening and relaxation .
| Trade Name | SC-37681 |
| Generic | Gemeprost |
| Gemeprost Other Names | Gemeprost, SC-37681 |
| Type | |
| Formula | C23H38O5 |
| Weight | Average: 394.552 Monoisotopic: 394.271924324 |
| Groups | Approved, Withdrawn |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
SC-37681 is a prostaglandin E1 analogue used for cervical dilation and, in combination with mifepristone, for pregnancy termination.
Indicated for the softening and dilatation of the cervix uteri prior to transcervical, intrauterine operative procedures in the first trimester of pregnancy or facilitating therapeutic termination of pregnancy in patients in the second trimester of gestation.
SC-37681 is also used to associated treatment for these conditions: Cervical Dilatation, Pregnancy termination therapy
How SC-37681 works
As a prostaglandin analog, gemeprost binds to prostaglandin E2 and E3 receptors as an agonist to cause myometrial contractions and progressive cervical dilation via tissue sensitization to oxytocin .
Toxicity
Serious or life-threatening adverse effects include coronary spasms with subsequent myocardial infarctions and uterine rupture following prolonged uterine hypertonia or abnormal uterine pain. More common adverse effects are nausea, vomiting, loose stools, diarrhea, lower abdominal or back pain, headache, mild pyrexia and flushing. Less common side effects include hypotension, chest pain palpitations, tachycardia, muscle weakness, dyspnea, chills and headache. Oral LD50 is 300 mg/kg in mouse, 980 mg/kg in rat and 3200 mg/kg in rabbit .
Elimination Route
Systemic absorption of gemeprost is limited with about 12-28% of administered dose of gemeprost reaching the systemic circulation . Following vaginal administration, peak plasma concentration is reached after 2-3 hours .
Elimination Route
About 50% of the dose eliminated as metabolites in the urine during the first 24 hours.
Innovators Monograph
You find simplified version here SC-37681
